138 related articles for article (PubMed ID: 37751118)
1. Letter to the Editor in Response to the Article Entitled "Selection Criteria for Completion Thyroidectomy in Follicular Thyroid Carcinoma Using Primary Tumor Size and TERT Promotor Mutational Status".
Behra DP; Mishra A
Ann Surg Oncol; 2023 Dec; 30(13):8545. PubMed ID: 37751118
[No Abstract] [Full Text] [Related]
2. Letter to Editor in Response to Article Entitled "Selection Criteria for Completion Thyroidectomy in Follicular Thyroid Carcinoma Using Primary Tumor Size and TERT Promotor Mutational Status".
Park H; Kim TY; Kim TH; Kim JH
Ann Surg Oncol; 2023 Dec; 30(13):8546-8547. PubMed ID: 37789109
[No Abstract] [Full Text] [Related]
3. Selection Criteria for Completion Thyroidectomy in Follicular Thyroid Carcinoma Using Primary Tumor Size and TERT Promoter Mutational Status.
Park H; Heo J; Ki CS; Shin JH; Oh YL; Son YI; Kim JS; Kim SW; Chung JH; Kim TY; Kim TH; Kim JH
Ann Surg Oncol; 2023 May; 30(5):2916-2925. PubMed ID: 36637642
[TBL] [Abstract][Full Text] [Related]
4. TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular Thyroid Carcinoma: Implications for Clinical Work-Up.
Stenman A; Hysek M; Jatta K; Bränström R; Darai-Ramqvist E; Paulsson JO; Wang N; Larsson C; Zedenius J; Juhlin CC
Endocr Pathol; 2019 Sep; 30(3):246-248. PubMed ID: 31154561
[TBL] [Abstract][Full Text] [Related]
5. Minimally invasive follicular thyroid carcinoma: completion thyroidectomy or not?
Delbridge L; Parkyn R; Philips J; Barraclough B; Robinson B
ANZ J Surg; 2002 Nov; 72(11):844-5. PubMed ID: 12437700
[No Abstract] [Full Text] [Related]
6. Diagnosis, treatment, and outcome of follicular thyroid carcinoma.
Emerick GT; Duh QY; Siperstein AE; Burrow GN; Clark OH
Cancer; 1993 Dec; 72(11):3287-95. PubMed ID: 8080485
[TBL] [Abstract][Full Text] [Related]
7. A Clinical Overview of Telomerase-Associated Aberrancies in Follicular Thyroid Tumors as Diagnostic and Prognostic Markers: Tert Alert!
Juhlin CC
Scand J Surg; 2020 Sep; 109(3):187-192. PubMed ID: 31131695
[TBL] [Abstract][Full Text] [Related]
8. 5hmC Immunohistochemistry: A Predictor of
Hysek M; Hellgren SL; Condello V; Xu Y; Larsson C; Zedenius J; Juhlin CC
J Histochem Cytochem; 2023 Aug; 71(8):451-458. PubMed ID: 37486076
[TBL] [Abstract][Full Text] [Related]
9. Selective treatment of differentiated thyroid carcinoma.
Gemsenjäger E; Heitz PU; Martina B
World J Surg; 1997 Jun; 21(5):546-51; discussion 551-2. PubMed ID: 9204746
[TBL] [Abstract][Full Text] [Related]
10. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
[TBL] [Abstract][Full Text] [Related]
11. Operative decision-making for follicular thyroid lesions: a community hospital system experience.
Grannan K; Snyder J; McDonough S; Engel A; Farnum J
Am Surg; 2011 Apr; 77(4):443-6. PubMed ID: 21679553
[TBL] [Abstract][Full Text] [Related]
12. Clear Cell Variant of a Follicular Thyroid Tumor With Uncertain Malignant Potential: A Case Report.
Juhlin CC; Bränström R; Shabo I; Höög A
Int J Surg Pathol; 2019 May; 27(3):290-293. PubMed ID: 30370813
[TBL] [Abstract][Full Text] [Related]
13. The surgical dilemma of primary surgery for follicular thyroid neoplasms.
Staubitz JI; Musholt PB; Musholt TJ
Best Pract Res Clin Endocrinol Metab; 2019 Aug; 33(4):101292. PubMed ID: 31434622
[TBL] [Abstract][Full Text] [Related]
14. Human telomerase reverse transcriptase gene expression and the surgical management of suspicious thyroid tumors.
Umbricht CB; Conrad GT; Clark DP; Westra WH; Smith DC; Zahurak M; Saji M; Smallridge RC; Goodman S; Zeiger MA
Clin Cancer Res; 2004 Sep; 10(17):5762-8. PubMed ID: 15355904
[TBL] [Abstract][Full Text] [Related]
15. TERT, HRAS, and EIF1AX Mutations in a Patient with Follicular Adenoma.
Topf MC; Wang ZX; Tuluc M; Pribitkin EA
Thyroid; 2018 Jun; 28(6):815-817. PubMed ID: 29669480
[TBL] [Abstract][Full Text] [Related]
16. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F
Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628
[TBL] [Abstract][Full Text] [Related]
17. TERT promoter mutational screening as a tool to predict malignant behaviour in follicular thyroid tumours-three examples from the clinical routine.
Hysek M; Paulsson JO; Wang N; Jatta K; Lindh C; Fuentes-Martinez N; Shabo I; Zedenius J; Juhlin CC
Virchows Arch; 2018 Nov; 473(5):639-643. PubMed ID: 29860621
[TBL] [Abstract][Full Text] [Related]
18. Does completion thyroidectomy improve the outcome of patients with minimally invasive follicular carcinoma of the thyroid?
Sugino K; Kameyama K; Nagahama M; Kitagawa W; Shibuya H; Ohkuwa K; Uruno T; Akaishi J; Suzuki A; Masaki C; Matsuzu K; Kawano M; Ito K
Ann Surg Oncol; 2014 Sep; 21(9):2981-6. PubMed ID: 24770681
[TBL] [Abstract][Full Text] [Related]
19. Refining Dynamic Risk Stratification and Prognostic Groups for Differentiated Thyroid Cancer With TERT Promoter Mutations.
Kim TH; Ki CS; Kim HS; Kim K; Choe JH; Kim JH; Kim JS; Oh YL; Hahn SY; Shin JH; Jang HW; Kim SW; Chung JH
J Clin Endocrinol Metab; 2017 May; 102(5):1757-1764. PubMed ID: 28323925
[TBL] [Abstract][Full Text] [Related]
20. Larger tumor size predicts nodal involvement in patients with follicular thyroid carcinoma.
Pisanu A; Deplano D; Pili M; Uccheddu A
Tumori; 2011; 97(3):296-303. PubMed ID: 21789006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
